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Parainfluenza virus 5 (PIV5 or SV5) infects several mammalian species but is restricted from efficient replication in mice. In humans, PIV5
evades IFN signaling by targeting STAT1 for proteasomal degradation in a STAT2-dependent reaction. In contrast, cell culture experiments have
demonstrated that the divergent murine STAT2 protein fails to support STAT1 targeting. Expression of human STAT2 in mouse cells can overcome
the species restriction to enable PIV5-induced STAT1 degradation and subsequent IFN antagonism. Here, we describe a transgenic mouse that
ubiquitously expresses human STAT2. PIV5 infection induces STAT1 degradation leading to enhanced virus replication and protein expression in
the cells from the transgenic mouse but not from the non-transgenic littermates. Importantly, intranasal inoculation with PIV5 results in increased
viral load in the lungs of the transgenic mice compared to wild-type littermates. These transgenic mice provide a small animal model to study the
role of innate immune evasion in paramyxovirus pathogenesis.
© 2007 Elsevier Inc. All rights reserved.Keywords: STAT1; STAT2; STAT4; Paramyxovirus; Interferon; Host evasion; Innate immunity; Virus-host interaction; Simian virus 5; SV5; ProteasomeIntroduction
The co-evolution of viruses with their hosts has resulted in
diverse mechanisms to subvert the anti-viral immune system
(Levy and Garcia-Sastre, 2001). Understanding how these
virulence factors affect viral pathogenesis is a critical first
step in identifying targets for pharmaceutical intervention or
vaccine development. The paramyxovirus PIV5 (previously
known as simian virus 5, SV5) has been isolated from human,
canine, porcine and non-human primate populations (Chat-
ziandreou et al., 2004). In canines, PIV5 has been implicated
in upper respiratory tract disease (kennel cough) and has been
isolated from the cerebral spinal fluid of a dog with posterior
paralysis (Appel and Bemis, 1978; Evermann et al., 1981). In⁎ Corresponding author. Pancoe ENH Pavilion Rm 4401, 2200 Campus Drive,
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doi:10.1016/j.virol.2007.10.001humans, PIV5 has been linked to both multiple sclerosis and
chronic fatigue and immune dysfunction syndrome (CFIDS),
although direct causative associations are poorly understood
(Goswami et al., 1984a,b, 1987; Brankin et al., 1989; Cosby
et al., 1989; McLean and Thompson, 1989) and (http://www.
ncf-net.org/library/PIV5HostChallenge-0606.htm). PIV5 can
persistently infect cells and has been isolated from several
cultured cell lines (Young et al., 2007). The observation that
humans are one of the favored hosts for PIV5 replication is
linked to the virus's efficacy in blocking type I and type II
interferon signaling as a result of the specific degradation of
the interferon signaling molecule, STAT1 (Didcock et al.,
1999a,b).
PIV5-induced STAT1 degradation requires the actions of a
single viral protein known as V. The V protein assembles de
novo STAT1-targeting ubiquitin ligases from cellular compo-
nents. This V-dependent degradation complex, known as the
VDC, is composed of a number of cellular proteins that directly
or indirectly bind to the V protein, including DDB1, the Cullin
family member Cul4A, and both STAT1 and STAT2 (Lin et al.,
Fig. 1. PIV5 V protein binds human but not mouse STAT2. Mouse NIH3T3 cells
or human 2fTGH and HEK293Tcells were transfected with either FLAG-tagged
PIV5 V protein (V) or FLAG vector control (C). Parallel samples of NIH3T3
were co-transfected with human STAT2 expression vector (hST2). Whole cell
extracts were immunoprecipitated with FLAG-M2 agarose beads, eluted with
SDS–PAGE buffer and processed for immunoblot with specific antibodies
indicated.
Fig. 2. Expression of human STAT2 in transgenic mice. (A) The 2555-bp open
reading frame encoding human STAT2 was flanked by the human ubiquitin C
promoter on the 5′ end and an SV40 splice site and poly A tail on the 3′ end.
(B) NIH3T3 cells were transfected with the 5xISRE-luciferase plasmid with or
without the hSTAT2 transgene construct, infected with PIV5 for 24 h prior to
luciferase assay. Normalized to co-transfected Renilla luciferase. Bars indicate
the mean normalized to percent of maximum (n=3) and error bars indicate
standard deviation. (C) Ubiquitous STAT2 expression in transgenic mice.
Protein extracts (20 μg) from isolated transgenic mice were subject to
immunoblot to detect human STAT2. Ubiquitous expression of the transgene
throughout the mouse was observed.
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Available evidence indicates that the combined actions of these
proteins produce an E3 ubiquitin ligase capable of targeting
STAT1 for proteasome-mediated degradation (Ulane and
Horvath, 2002). PIV5 V associates with STAT2, which serves
as an interface for recruitment of the target, STAT1. Evidence
suggests that the V protein forms a subcomplex with cellular
ubiquitin ligase machinery, including DDB1, Cul4A and Roc1.
The V protein assembles the two subcomplexes, forcing the
interaction of the hijacked ubiquitinylation machinery with the
STAT1 protein target, enabling the modification of STAT1 to
signal its destruction (Ulane et al., 2005; Precious et al., 2005). V
proteins also impinge upon IFN biosynthesis mediated by the
MDA5 RNA helicase (Andrejeva et al., 2004), but this reaction
is not dependent on STAT2.
PIV5-dependent STAT1 degradation in human cells is
contingent upon the expression of human STAT2, and the
failure to induce STAT1 degradation in infected mouse cells has
been attributed to the significant divergence in STAT2 between
mice and humans (Park et al., 1999). Indeed, PIV5 V protein
cannot inhibit IFN signaling in mouse cells (Didcock et al.,
1999a). Apparently mouse STAT2 cannot efficiently substitute
for human STAT2 in the VDC. Expression of human STAT2 in
mouse cell lines enables the V protein to target STAT1 for
proteasome-mediated degradation and block IFN signaling,
allowing PIV5 to replicate more efficiently, even in the presence
of exogenous IFN (Parisien et al., 2002a).
To validate these observations in an intact animal, and as a
means to establish a model system to better understand how the
ability to block IFN signaling affects viral pathogenesis in vivo,
a transgenic mouse ubiquitously expressing human STAT2
(hSTAT2) was created. These mice are normal by all criteria, but
unlikeWTmice, infection with PIV5 induces loss of STAT1 and
inhibition of IFN signaling, recapitulating the phenotype ob-
served in cultured cells. Furthermore, results indicate that the
enabled IFN signaling inhibition is advantageous to virus
replication in vivo, as the lungs of PIV5 infected transgenic mice
contain more virus than wild-type mice. The increased viral load
resulted in a coordinate increase in the expression of inflam-
matory signaling proteins.Results
PIV5 V preferentially binds to STAT2 from human and not mouse
It has been previously shown that PIV5 V protein can target
STAT1 for degradation in human cell lines, and that this
degradation is dependent on the expression of STAT2 (Parisien
et al., 2002a). In mouse cell lines, expression of human STAT2 is
required for PIV5 to target the degradation of STAT1 (Parisien
et al., 2002b). To better understand the mechanisms underlying
the species specificity, we performed co-immunoprecipitations
to examine V:STAT2 interactions. The mouse cell line NIH-3T3
was transfected with FLAG-tagged PIV5 V protein with and
without co-expression of human STAT2. Immunoprecipitations
show that human STAT2 can readily associate with the PIV5 V
protein while mouse STAT2 cannot (Fig. 1). These results
verified the earlier assumption that PIV5 V protein fails to
recognize murine STAT2 and suggested it may be possible to use
a transgene approach to engineer PIV5 susceptible mice.
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A transgenic mouse expressing human STAT2 broadly in
vivo was desired. A plasmid vector was constructed by engi-
neering the human STAT2 ORF downstream of the murine
ubiquitin C gene promoter (Fig. 2A). The ability of this human
STAT2 vector to enable PIV5 V protein-mediated IFN signaling
interference was tested using reporter gene assays in mouse
cells. In murine NIH-3T3 cells, PIV5 infection does not inhibit
IFN-induced luciferase activity, but expression from the
ubiquitin C-human STAT2 construct resulted in PIV5-dependent
inhibition of IFN responsive transcriptional activity (Fig. 2B).Fig. 3. Human STAT2 activity in mouse does not alter IFN signaling. (A) Splenocytes
Cells were immediately lysed and processed for immunoblot with antibodies that reco
STAT2 and STAT1α/β (recognizes human and mouse). (B) Splenocytes from tran
preparation and anti-STAT1 immunoprecipitation. Precipitated proteins were separa
STAT2, mouse STAT2 and tyrosine phosphorylated STAT2. (C) Splenocytes from hST
18 h prior to RNA isolation and reverse transcription. Real-time PCR with primers
indicate average values for n=3, with error bars to represent standard deviation. (D
infected with VSV (1 pfu/cell) for 16 h. Infectious virus released into the supernatant
protection in transgenic andwild-type cells. Graph shows data from an individual VSV
mice and stimulated with IFNβ for 20′ prior to lysis. Whole cell extracts were sepa
tyrosine phosphorylated STAT4. IFNβ induces STAT4 activation in both wild-type aThis vector was linearized and used for microinjection into
fertilized eggs that were implanted into pseudo-pregnant sur-
rogate mothers for generation of transgenic mice.
Primary screening of live born pups was carried out by PCR
analysis of total DNA to detect the human STAT2 sequences.
Screening was followed by examining STAT2 protein expres-
sion by immunoblotting. To test for transgenic protein expres-
sion levels, an antibody recognizing the C-terminal region
specific to human STAT2 was used. The transgenic mice were
found to express human STAT2 in all tissues analyzed, including
liver, thymus, kidney, lung and spleen (Fig. 2C), as well as bone
marrow and brain (not shown). Two males exhibiting moderatefrom transgenic and wild-type mice were treated with murine IFNβ for 5–30min.
gnize human and mouse tyrosine phosphorylated STAT2, human STAT2, mouse
sgenic and wild-type mice were treated with IFNβ for 10 min prior to lysate
ted by SDS–PAGE and processed for immunoblot with antibodies for human
AT2 transgenic and wild-typemice were isolated and treated with mIFNβ for 6 or
specific for Mx1 and Ifi47 were performed and normalized to GAPDH. Graphs
) Transgenic and wild-type MEFs were pretreated 2 h with murine IFNβ, then
was estimated by titration on CV1 cells. IFN treatment provides a similar level of
titration experiment. (E) Splenocyteswere isolated from transgenic andwild-type
rated by SDS–PAGE and immunoblotted with antibodies to detect STAT4 and
nd transgenic splenocytes.
199T.A. Kraus et al. / Virology 371 (2008) 196–205to high expression of human STAT2 protein in PBMCs were
chosen to generate two independent colonies that behaved
similarly in all experiments.
Human STAT2 is activated by mouse IFN stimulation
Although it has been shown that murine STAT2 can
complement IFN signaling defects in STAT2-deficient human
cells (Paulson et al., 1999), the ability of human STAT2 to
participate in the murine IFN response complex has not been
characterized. To address this question, the activity of human
STAT2 in the transgenic mice was characterized. Activation of
STAT2 can be evaluated using antiserum specific for the
tyrosine-phosphorylated form. This reagent reacts well with
both phosphorylated human STAT2 (Y690) and phosphorylated
mouse STAT2 (Y689). Splenocytes from transgenic and wild-
type mice were treated with IFNβ for 5 to 30 min, and cell
extracts were subjected to immunoblot with phosphorylated
STAT2 antiserum. Both the endogenous murine STAT2 and the
ectopic human STAT2 were found to be activated in response to
IFN stimulation (Fig. 3A). To test the downstream conse-
quences of hSTAT2 activation, the ability to form heterodimers
with murine STAT1 was tested by Co-IP assay.
The tyrosine phosphorylated hSTAT2 was also found to
heterodimerize with STAT1 in IFN-treated splenocytes (Fig.
3B). This result led us to consider the possibility that if it were
rate limiting, addition of human STAT2 might influence the
quality of IFN responses of the cell. To analyze IFN signaling in
the transgenic cells, we performed RT-PCR analysis of IFN-
stimulated target genes (ISGs). Treatment of splenocytes with
IFNβ resulted in increased mRNA accumulation for all ISGs
tested, including Mx1 and Ifi47 (Fig. 3C). No significant
differences were found between WT and transgenic IFN
responsive gene expression. To test the biological activity of
IFN antiviral responses in the mice, transgenic and wild-type
MEFs were infected with vesicular stomatitis virus (VSV), a
virus known to be sensitive to the IFN-induced antiviral state.
The sensitivity of VSV to the IFN response did not differ
between the hSTAT2 transgenic and wild-type MEFs (Fig. 3D
illustrates representative results). Therefore, we conclude that
although human STAT2 can get activated by the murine IFNFig. 4. PIV5 targets STAT1 for degradation and blocks IFN signaling only in transge
(50 pfu/cell) for 24 h prior to lysis and immunoblot with STAT1 or P/V antibod
immunofluorescence microscopy. Viral proteins are detected in infected cells by Texas
Fig. 2. IFN signaling is inhibited only in the infected transgenic mice.system and participate in the ISGF3 complex formation, the
general biological consequences for IFN signaling and anti-viral
responses in the human STAT2 transgenic mice are minimal.
Activation of STAT4
One other controversial aspect of IFN responses attributed to
sequence diversity between human and mouse STAT2 is the
ability of IFN to induce STAT4 tyrosine phosphorylation (Farrar
et al., 2000a,b). As differential STAT4 activation might con-
tribute to immune responses in our transgenic mice we tested the
hSTAT2 transgenic mice for differences in IFN-induced STAT4
tyrosine phosphorylation. Splenocytes from transgenic and
wild-type siblings were treated with IFNβ for 20 min before
processing for immunoblot with antisera that recognizes tyrosine
phosphorylated STAT4 (Fig. 3E). STAT4 tyrosine 693 phos-
phorylation was detected in both WT mice and transgenic mice
at similar levels. These data support the conclusion that activa-
tion of STAT4 by IFN occurs equally well in murine splenocytes
regardless of the presence or absence of human STAT2 expres-
sion, consistent with the results of (Nguyen et al., 2002). More-
over, this result confirms that the IFN signaling pathway is intact
in the transgenic mice and does not differ significantly fromWT
littermates.
Human STAT2 transgene supports PIV5-mediated
STAT1 degradation
To characterize the ability of the transgenic mice to support
PIV5-mediated STAT1 targeting and inhibit IFN signaling,
transgenic and wild-type MEFs were infected with PIV5 for
24 h. While STAT1 levels were unaffected in the wild-type
MEFs, STAT1 was greatly reduced in the transgenics (Fig. 4A).
To verify STAT1 targeting on a single cell level, indirect im-
munofluorescence was performed. In the wild-type cells, STAT1
was readily detected at a level similar to adjacent uninfected cells
(Fig. 4B). In cells from the transgenic mice, STAT1 was absent
from infected cells. Therefore, the basic properties of PIV5-
induced STAT1 destruction were recapitulated in the transgenic
mouse cells. The ability of PIV5 to alter the IFN response was
tested using a reporter gene assay. Transgenic and wild-typenic mice. (A) MEFs from wild-type or transgenic mice were infected with PIV5
y. (B) MEFs were infected with PIV5 (1 pfu/cell) and prepared for indirect
Red. STAT1 is detected by FITC. (C) Luciferase assay in MEFs carried out as in
Fig. 5. Transgenic mouse cells support enhanced PIV5 replication. (A) MEFs were infected with PIV5 for 24 h before additional (1000 U/ml) exogenous IFNβ for
another 24 h. Cells were lysed and processed for immunoblot with human STAT2 and P/Vantibodies. (B) PIV5 titer from MEFs infected at low MOI (1 pfu/cell) with
PIV5 after 24 and 48 h. Viral supernatant was titered by serial dilution on CV-1 cells. Results show greater viral replication in transgenic MEFs.
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reporter gene prior to PIV5 infection. Twenty-four hours post-
infection, cells were treated with IFN for 12 h. The results showFig. 6. Enhanced replication in vivo. Groups of transgenic mice were intranasally inoc
were euthanized and lungs were processed for infection virus, RNA and histolog
determined by plaque assays on CV1 cells. (B) Histological evaluation. At 48 hpi, l
sections of WT and hSTAT2 mice with and without PIV5 infection. (C) RNAwas iso
specific primers for PIV5 NP, IFNβ, Mx1, Ifi47, IP10, IL6, MCP1 and RANTES.that while IFN signaling can occur in both the transgenic and
wild-type cells in the absence of PIV5 infection, only the wild-
type can retain this activity after PIV5 infection (Fig. 4C).ulated with PIV5 (4×105 pfu/mouse). Forty-eight to 72 h post-infection, the mice
ical analysis. (A) Concentration of infectious virus in lung homogenates was
ungs were fixed and sectioned for H&E staining. Micrographs illustrate typical
lated from lung homogenates 72 hpi and real-time RT-PCR was performed with
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primary cells
This acquired ability to block IFN activity should result in a
replication advantage for the virus. To test the biological
outcome of PIV5-mediated IFN evasion, wild-type and
transgenic MEFs were infected with PIV5 at a low MOI (0.1
and 1) for 24 h, then treated with or without IFN for 24 h prior to
lysis and immunoblot for viral protein expression. Greater
accumulation of viral protein was detected in the infected
transgenic cells compared to wild-type (Fig. 5A, compare PIV5
P protein expression, lanes 9 to 4 and lanes 7 to 2). Furthermore,
in the wild-type cells, IFN treatment caused a marked reduction
in viral protein synthesis (compare PIV5 P protein expression in
lanes 2 to 3, or lanes 4 to 5). In contrast, the transgenic cells were
less sensitive to IFN stimulation (compare PIV5 P expression in
lanes 7 to 8, lanes 9 to 10).
Furthermore, PIV5 gained a replication advantage in the
transgenic MEFs, achieving a higher titer within 24 h compared
to wild-type (Fig. 5B). The viral load in the transgenic cells
remained high at 48 hpi, a time where WT MEFs exhibit a
decline in virus load. This confirms that the ability to limit PIV5
replication is impaired in the transgenic mice.
Transgenic mice support greater PIV5 replication in vivo
The analysis of transgenic mouse cells indicates that human
STAT2 enables PIV5-mediated STAT1 destruction, IFN
signaling evasion and more efficient virus replication. To
test the theory that this enabled IFN evasion increases PIV5
replication in vivo, transgenic and wild-type mice were
infected intranasally with PIV5 and analyzed 72 h later.
While PIV5 was detected in both wild-type and transgenic
mouse lungs, the hSTAT2 transgene resulted in an increase in
lung viral titers by an average of one hundred fold (Fig. 6A).
This result supports the conclusion that PIV5-mediated STAT1
degradation in the lungs of the transgenic mice can dampen
the innate antiviral response and allow for unrestricted viral
replication.
Despite the greater virus replication at 72 hpi, histological
assessment of infected lungs did not reveal substantial differ-
ences in pathology at 48 hpi. However, areas of greater inflam-
matory cell infiltration were observed at greater frequency in
infected transgenic mouse lungs (Fig. 6B), suggesting a response
to the increased viral load. Tomeasure inflammation in the lungs
of these mice, we isolated RNA from the lung homogenates and
performed real-time PCR for inflammatory cytokines and inter-
feron stimulated gene expression. Fig. 6C shows that there is
higher expression of the cytokines IL6, MCP1 and Rantes, and
higher expression of the IFN stimulated genes Mx1 and Ifi47 in
the lungs of the infected transgenic mice. IFNβ itself is induced
in infected lungs, but the transgenic animals exhibited a lower
maximum level at this time point. It is interesting to note that
when the virus has the ability to inhibit IFN signaling, the
resulting increased viral load stimulates a greater anti-viral
response. Taken together, these experiments show that viral IFN
evasion of PIV5 results in an immediate increase in viral repli-cation at the site of primary infection followed by an increase in a
local inflammatory response.
Discussion
PIV5 is a zoonotic virus found in humans whose pathogen-
esis is uncertain. In immuno-competent mice, PIV5 appears to
be non-pathogenic. However, because its normal IFN evasion
strategies are compromised, efficient replication of the virus is
restricted from mice. Viral attachment and entry often appears to
be a factor for species specificity as well as cell tropism for
many viruses including certain paramyxoviruses. However, for
PIV5, restriction of mice from the host range is in large part
dictated by the ability to block IFN signaling in a species
specific fashion. For this virus, restriction from mice is
conferred in part by the inability to use the intracellular signal
transducer and activator of transcription, STAT2, as a cofactor to
degrade murine STAT1.
In the human STAT2-expressing transgenic mice described
here, PIV5 is better able to recapitulate the human infection due
to the enabled block in IFN signaling, a critical parameter for
viral pathogenesis.
In this unique animal infection model, IFN signaling and
antiviral responses remain intact, providing the ability to exam-
ine virus replication in a more natural context of a fully
immune-competent host. This situation differs greatly from
strategies used previously to investigate PIV5 immune
responses and pathogenesis. In previous reports, immune
compromised mice were used to study the immune response
to and pathogenesis of PIV5 infections. When SCID mice were
used, PIV5 infection resulted in a short-term weight loss and
efficient recovery from infection, leading to the conclusion that
the adaptive immune system is not vital to the antiviral immune
response to PIV5 (Young et al., 1990). Indeed these studies
were the first to demonstrate the importance of IFN responses in
controlling PIV5 infection. Later studies took advantage of mice
harboring a deficiency in the STAT1 gene. In this situation, the
host is systemically deficient in responses to both type I and
type II IFNs, causing dramatic consequences on innate and
adaptive immunity. Infection of STAT1 deficient mice with
PIV5 results in 100% mortality (He et al., 2002), dramatically
different from the outcome of any natural PIV5 infection
reported. These data prove that the virus can replicate efficiently
in mice, and that the innate immune response is critical.
However, a drawback to these immune-compromised mouse
experiments is that it is not possible to determine the natural
progression of pathogenesis during infection or evaluate the
contributions of host responses to viral pathogenesis. Based on
our analysis of SV5-dependent STAT2 degradation in the
cultured transgenic mouse cells, during a natural PIV5
infection, we expect that STAT1 would be degraded in the
infected cells, leaving the STAT1-dependent immune response
of non-infected cells intact.
Although PIV5 does not robustly infect murine cells for
reasons that may include differences in receptor binding and
membrane fusion as well as immune effects, low level persistent
infections can be established in cultured mouse cells. It has been
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can result in the selection of mouse adapted variants (Young
et al., 1997). One isolate, termed mci-1, was found to be highly
fusogenic and had acquired the ability to spread more rapidly
than wild-type virus via cell to cell fusion. The second isolate,
mci-2, contained a mutation in the P/V gene that allowed for
more efficient IFN evasion in the mouse cells (Young et al.,
2001). When a recombinant PIV5 was constructed harboring
the P/V gene mutation (N100D), greater virus replication in
murine cells was observed. It has been proposed that the N100D
mutation may enable greater interaction with murine STAT2 to
facilitate destruction of STAT1, but the ability of this mouse
adapted virus to replicate in animals has not been reported. This
result reinforces the importance of STAT2 in STAT1 destruc-
tion, IFN evasion and virus replication.
It is quite interesting to note that in infected transgenic mice,
where IFN evasion has led to an early increase in viral load,
there is a parallel increase in inflammatory response. Based on
these findings, it is tempting to speculate that PIV5-mediated
IFN evasion offers only a short-lived advantage to the virus, and
that clearance by the host immune system occurs efficiently
with or without IFN evasion. In other words, the consequence of
IFN evasion for PIV5 is an increase in the viral load at the
primary site of infection, providing a short-term increase in viral
load that also may heighten the chance of horizontal
transmission. Further experimentation is required to test this
concept.
PIV5 has long served as a prototypic member of the larger
Paramyxovirus family. This family of viruses includes re-
emerging viruses like measles and mumps, as well as newly
emerging deadly viruses Hendra and Nipah virus. All of these
pathogenic paramyxoviruses express V proteins which inhibit
IFN responses (Horvath, 2004). In all cases, the consequence of
IFN evasion has only been examined in vitro. The human
STAT2 transgenic model described here provides an excellent
experimental system to probe the consequences of innate
immune evasion during infection of an intact host organism.
The data reported here lay the foundation to study the role that
IFN evasion has on adaptive immune responses, viral
pathogenesis, disease progression, virus clearance and virus
transmission.
Materials and methods
Cell lines, transfections and viruses
PIV5 (strain W3A, derived from a genetically defined re-
combinant virus system; He et al., 1997; Keller et al., 2001) was
propagated and titered in CV-1 cells (African green monkey
kidney cells). NIH 3T3 cells (gift from Stuart Aaronson, Mount
Sinai School of Medicine, New York), 293T cells and 2fTGH
and U6A cells were maintained in DMEM supplemented with
10% cosmic calf serum (Hyclone). 2fTGH and U6A cells were
transfected by Superfect (Qiagen), 293Twere transfected by the
calcium phosphate method and 3T3 cells were transfected by
Lipofectamine 2000 (Invitrogen) according to the manufac-
turer's instructions.Generation of transgenic mice
The construct containing the 5′ flanking region (−1225 to
−6) of the human ubiquitin C gene was a kind gift of Dr. Peter
Angel (Heidelberg, Germany). The full-length human STAT2
cDNAwas subcloned into the multiple cloning site upstream of
an 850-bp SV40 splice site and poly A region (Fig. 1A). The
construct was tested for protein expression and for PIV5-
dependent STAT1 degradation in U6A cells (STAT2−/−) before
microinjection of the purified DNA into both B6C3 hybrids and
pure Balb/c backgrounds by the Mount Sinai mouse genetics
facility (Mount Sinai Medical Center, New York, NY). Two
different transgenic lines were constructed, one with B6C3
background and the other with Balb/c background. The in vivo
experiments were carried out on the Balb/c background, while
in vitro experiments were carried out in B6C3. In both back-
grounds, the human STAT2 transgene enabled efficient PIV5 V-
mediated IFN signaling evasion. Of the 65 pups born in B6C3
hybrids, 23 had integration of the transgene as assayed by tail
tip genomic PCR. Of the 16 pups born in the Balb/c back-
ground, 8 had integration. Most had moderate to high human
STAT2 protein expression in peripheral blood cells. Indepen-
dent lines were generated by mating a male founder with wild-
type C57BL/6 or Balb/c females (Charles River Laboratories).
Experiments were carried out with first generation transgenic
and wild-type sibling littermates.
Generation of MEFs
Male transgenics were mated to C57BL/6 or Balb/c females,
depending on the background of the transgenics. MEFs were
generated by harvesting day 14 embryos from matings between
male transgenics and wild-type females by removing the head
and liver and running them through a 5-cc syringe fitted with an
18-gauge needle. The resulting tissue was pipetted up and down
in 5 ml Trypsin/EDTA solution (Gibco), and incubated for
15 min at 37 °C. Tissue was pipetted again, then 15 ml DMEM
with 10% Cosmic calf serum (Hyclone) was added and the cells
were cultured undisturbed for 48 h. Media were changed and the
cultures of primary fibroblasts were allowed to expand. Each
embryo was cultured separately and genotyped to confirm ex-
pression of the transgene.
Primary cell cultures
For splenocytes, spleens were teased into single cell suspen-
sions and depleted of RBCs with 0.75% NaHPO4. Cells were
cultured in DMEM supplemented with 10% CCS, 1%
penicillin–1% streptomycin (Gibco), L-glutamine (Gibco),
non-essential amino acids (Gibco) and 2-mercapto-ethanol
(5×10−5 M). For IFN activation, mouse IFNβ (PBL, Piscat-
away, NJ) was used at a concentration of 103 U/ml.
Protein immunoblot assays
Phosphospecific antibodies against STAT2 and STAT4 as
well as antibodies against murine STAT4 and the unique C-term
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Biotechnology (Santa Cruz, CA) and used according to the
manufacturer's instructions. DDB1 antibody was purchased
from Pharmingen (San Diego, CA). Anti-PIV5 P/V protein
antibody was purchased from Serotec (Raleigh, NC). Polyclonal
antisera against murine STAT2 was a kind gift of Dr. Christian
Schindler (Columbia University). Total protein extracts were
prepared in whole cell extract buffer (50 mM Tris pH 8.0,
280 mM NaCl, 0.5% IGEPAL, 0.2 mM EDTA, 2 mM EGTA,
10% glycerol, 1 mM DTT) supplemented with a protease
inhibitor cocktail (Complete, Roche), 1 mM DTT and 10 nM
Na3VO4. Proteins were separated by SDS–PAGE and trans-
ferred to nitrocellulose filters, immunoblotted by standard
procedures, and prepared for chemiluminescent detection
according to manufacturer's protocol (NEN Renaissance).
For STAT1 immunoprecipitations, cell extracts were incu-
bated with 1 μg antibody overnight followed by 30 μl protein
A-agarose beads (Roche) in 50% slurry for 1 h and washed five
times with 1 ml of whole-cell extract buffer. Samples were
boiled in 30 μl of SDS gel loading buffer, and 15 μl was loaded
directly onto an SDS polyacrylamide gel for analysis. For
FLAG immunoprecipitations, lysates were precleared and incu-
bated with (anti-FLAG) M2 beads (Sigma) for 4 h, washed 5
times followed by addition of SDS gel loading buffer.
Indirect immunofluorescence
For indirect immunofluorescence experiments, MEFs from
transgenic and non-transgenic embryos were grown to 60 to
80% confluence on Permanox chamber slides (Nalgene Nunc)
and infected with PIV5 at an MOI of 1. At 24 h post-infection,
cells were fixed in 1% formaldehyde in PBS for 15 min and
permeabilized in an ice-cold methanol–acetone solution (1:1)
for 10 min at −20°C. After five washes with PBS, samples
were blocked with 1% bovine serum albumin in PBS for
15 min at 37°C. After every subsequent antibody exposure,
samples were washed and blocked. Antibody staining was
performed sequentially, with the PK antibody at a 1:100
dilution first, followed by an Texas red-conjugated mouse
immunoglobulin G (Jackson ImmunoResearch Laboratories,
West Grove, Pa) to visualize PIV5 P/V protein. The second
stain for STAT1 was detected with fluorescein isothiocyanate-
conjugated rabbit immunoglobulin G (Jackson ImmunoRe-
search Laboratories). STAT1 polyclonal antisera used for
immunofluorescence were precleared on fixed and permeabi-
lized STAT1-deficient U3A cells to reduce non-specific
background staining. Images were obtained using a Leica
TCSSP confocal microscope.
RNA analysis of splenocytes
Total RNA was prepared by using Trizol reagent (GIBCO
BRL), digested with DNase I (Promega) and subjected to
reverse transcriptase with SuperScript III Reverse Transcriptase
(Invitrogen) as per manufacturer's recommendations. Mock
reactions were carried out with no reverse transcriptase added to
confirm the absence of genomic DNA. Real-time PCR wasperformed on the MX3000 (Stratagene) by a three step protocol
with a denaturation temp of 94 °C, an annealing temp of 61 °C
and a 72 °C extension. The primer sets were as follows: Mx1-S
5′-gactaccactgagatgaccc-3′, Mx1-AS 5′-ctctatttcctccccaaatg-3′,
Ifi47-S 5′-ttgcctgaacaagaacagtg-3′, Ifi47-AS 5′-aagttccccctt-
gatgtctg-3′, GAPDH-S 5′ ggcatggactgtggtcatga-3′, GAPDH-
AS 5′-caccaccatggagaaggca-3′. Mx1 and Ifi47 products were
normalized against GAPDH. Untreated RNA was used as the
calibrator.
Antiviral assays
Antiviral assays titering PIV5 and vesicular stomatitis
virus (VSV) were performed as follows: Cells were washed
with serum free media (SFM), infected with virus at the
indicated multiplicity of infection (MOI) for 2 h, washed with
SFM, and cultured in DMEM with 2% CCS. Supernatants
were then titered in plaque assays using simian CV-1 cells
with an overlay containing 0.5% agar with DMEM, 10 mM
HEPES (pH 7.2), and 1% pen/strep (Gibco). After plaque
formation, the monolayer was fixed in 3.7% formaldehyde
and stained with 0.1% crystal violet (Sigma) dissolved in
20% ETOH.
Reporter gene assays
MEFs were plated for 80–90% confluency the following
day. Cells were transfected using Lipofectamine 2000
(Invitrogen, Carlsbad, CA) with 5× ISRE-luciferase and
Renilla (Promega, Madison, WI) constructs. Cells were
cultured for 24 h before the addition of IFNβ (103 u/ml) for
12 h. In experiments where PIV5 infection is used, transfected
cells were cultured overnight before infection with PIV5
(10 pfu/cell) in serum free media. Twenty-four hours post-
infection, all cells were washed and cultured with DMEM with
2% Cosmic calf serum, +/−IFNβ.
Infection of mice
While anesthetized with an intraperitoneal administration of
2,2,2-Tribromoethanol (Avertin), mice were infected with an
intranasal inoculation of 4×105 plaque forming units of PIV5 in
10 μl DMEM. Control mice were subjected to anesthesia and
intranasal administration of sterile PBS. At 48–72 h post-
infection, mice were euthanized and their lungs were removed
for analysis.
Analysis of infected mouse lung
Whole lung was removed, rinsed in PBS, blotted dry and
transferred to a 14-ml round bottom tube (Fisher) with 1 ml ice-
cold homogenate buffer (DMEM supplemented with 0.75%
BSA, 2 mM L-glutamine, 1% pen/strep, 10 mM HEPES, pH
7.2). Tissue was homogenized using a Powermax 250 (VWR)
for two 10-s bursts, followed by incubations on ice. Tissue
homogenate was then used for virus titering on CV-1 cells or for
RNA analysis. For RNA analysis for homogenates, 100 μl of
204 T.A. Kraus et al. / Virology 371 (2008) 196–205homogenated tissue was added to 1 ml Trizol. RNA isolation
and cDNA synthesis was performed as above. Real-time PCR
was performed using specific primers listed below:
PIV5NP S 5′-tatgctgatgcaggcacccatg-3′, AS 5′-tctggatgtc
caaggccacttg-3′
IFNβ S 5′-acctacagggcggacttcaag-3′, AS 5′-gatggcaaagg
cagtgtaactctt-3′
IP10 S 5′-tccttgtcctccctagctca-3′, AS 5′-ataaccccttgggaa
gatgg-3′
IL6 S 5′-agttgccttcttgggactga-3′, AS 5′-cagaattgccattgca
caac-3′MCP1 S 5′-cccaatgagtaggctggaga-3′, AS 5′-tctggacccattcctt
cttg-3′
RANTES S 5′-gcccacgtcaaggagtatttcta-3′, AS 5′-acacacttgg
cggttccttc-3′
Histology of lungs
Mice were infected as above. At 48 h post-infection, mice
were anesthetized and lungs were perfused with formalin before
removal for fixation. 10 mm longitudinal cross-sections were
prepared for hematoxylin and eosin (H&E) staining.
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